296 related articles for article (PubMed ID: 34350252)
21. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
[TBL] [Abstract][Full Text] [Related]
22. Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
Kiura K; Yoh K; Katakami N; Nogami N; Kasahara K; Takahashi T; Okamoto I; Cantarini M; Hodge R; Uchida H
Cancer Sci; 2018 Apr; 109(4):1177-1184. PubMed ID: 29363250
[TBL] [Abstract][Full Text] [Related]
23. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
24. A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L).
Yamaguchi H; Wakuda K; Fukuda M; Kenmotsu H; Mukae H; Ito K; Chibana K; Inoue K; Miura S; Tanaka K; Ebi N; Suetsugu T; Harada T; Kirita K; Yokoyama T; Nakatani Y; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
J Thorac Oncol; 2021 Dec; 16(12):2121-2132. PubMed ID: 34419684
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
Xing L; Pan Y; Shi Y; Shu Y; Feng J; Li W; Cao L; Wang L; Gu W; Song Y; Xing P; Liu Y; Gao W; Cui J; Hu N; Li R; Bao H; Shao Y; Yu J
Clin Cancer Res; 2020 Dec; 26(23):6168-6175. PubMed ID: 32817079
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
[TBL] [Abstract][Full Text] [Related]
27. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
Nokihara H; Ogino H; Mitsuhashi A; Kondo K; Ogawa E; Ozaki R; Yabuki Y; Yoneda H; Otsuka K; Nishioka Y
BMC Cancer; 2022 Jun; 22(1):597. PubMed ID: 35650550
[TBL] [Abstract][Full Text] [Related]
29. Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.
Yi Y; Cai J; Xu P; Xiong L; Lu Z; Zeng Z; Liu A
J Transl Med; 2022 Mar; 20(1):122. PubMed ID: 35287683
[TBL] [Abstract][Full Text] [Related]
30. A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report.
Shan CG; Wang H; Lin T; Liu D; Wen L; Chen ZJ; Zhen JJ; Lai MY; Zhang L; Zou X; Hong WP; Cai LB
Ann Palliat Med; 2021 May; 10(5):5897-5901. PubMed ID: 33977730
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Ramalingam SS; Yang JC; Lee CK; Kurata T; Kim DW; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett JC; Thress KS; Jänne PA
J Clin Oncol; 2018 Mar; 36(9):841-849. PubMed ID: 28841389
[TBL] [Abstract][Full Text] [Related]
32. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
34. Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases.
Ye Q; Xu Y; Zhao J; Gao X; Chen M; Pan R; Zhong W; Wang M
Transl Oncol; 2023 May; 31():101637. PubMed ID: 36867956
[TBL] [Abstract][Full Text] [Related]
35. Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study.
Mu Y; Xing P; Hao X; Wang Y; Li J
Cancer Manag Res; 2019; 11():9243-9251. PubMed ID: 31802944
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.
Tang X; Li Y; Qian WL; Yan WF; Pang T; Gong YL; Yang ZG
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2475-2486. PubMed ID: 34536138
[TBL] [Abstract][Full Text] [Related]
37. Standard dose osimertinib for erlotinib refractory T790M-negative
Arulananda S; Do H; Rivalland G; Loh Z; Musafer A; Lau E; Mitchell P; Dobrovic A; John T
J Thorac Dis; 2019 May; 11(5):1756-1764. PubMed ID: 31285867
[TBL] [Abstract][Full Text] [Related]
38. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
Lin YT; Tsai TH; Wu SG; Liu YN; Yu CJ; Shih JY
Lung Cancer; 2020 Jul; 145():1-9. PubMed ID: 32387812
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
Wang X; Cai J; Zeng Z; Liu A
BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]